Viola Klück

Dapansutrile, an oral selective NLRP3 inflammasome inhibitor, for treatment of gout flares: an open-label, dose-adaptive, proof-of-concept, phase 2a trial

Viola Klück, Tim Jansen, M. Janssen et al. · The Lancet Rheumatology · 2020 · 257 citations · Full text

Anti-inflammatory, Gouty Arthritis, Pharmacology +8

Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout

David Bursill, William J. Taylor, Robert Terkeltaub et al. · Annals of the Rheumatic Diseases · 2019 · 112 citations · Full text

In vitro induction of trained immunity in adherent human monocytes

Jorge Domínguez‐Andrés, Rob J.W. Arts, Siroon Bekkering et al. · STAR Protocols · 2021 · 85 citations · Full text

Rare genetic variants in interleukin-37 link this anti-inflammatory cytokine to the pathogenesis and treatment of gout

Viola Klück, Rosanne C. van Deuren, Giulio Cavalli et al. · Annals of the Rheumatic Diseases · 2020 · 66 citations

Interleukin-37 treatment of mice with metabolic syndrome improves insulin sensitivity and reduces pro-inflammatory cytokine production in adipose tissue

Dov B. Ballak, Suzhao Li, Giulio Cavalli et al. · Journal of Biological Chemistry · 2018 · 49 citations · Full text